Outcome of 67 patients with solid tumors relapsed after high-dose chemotherapy and peripheral blood stem cell transplantation

Bone Marrow Transplantation

Volumn 31, Issue 11, 2003, Pages 995-1000

  Bojko, P ^a   Akca, A ^a   Seeber, S ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

HDC; Relapse; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; THIOTEPA; TRASTUZUMAB; TREOSULFAN; VINDESINE;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; DRUG RESPONSE; DYSPNEA; EDEMA; FEMALE; FEVER; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OVARY CANCER; PAIN; PERIPHERAL BLOOD STEM CELL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR; TESTIS CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037671560     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704047     Document Type: Article

References (20)

1. Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A for the European Group for Blood and Marrow Transplantation. Hematopoietic stem cell transplantation activity in Europe in 1999. Bone Marrow Transplant. 2001; 27: 899-916.
2. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069-1076.
3. Peters W, Rosner G, Vredenburgh J et al. A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 1999; 18: 1a (abstract).
4. Schrama JG, Faneyte IF, Schornagel JH et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol 2002; 13: 689-698.
5. Bojko P, Scharifi M, Stössel K, Seeber S: Comparison of processing four and five times the patients' blood volume during peripheral blood stem cell collection and analysis of CD34 + 38- and CD34 + 49d + subsets during apheresis. J Cancer Res Clin Oncol 2002; 128: 19-28.
6. Peters WP, Ross M, Vredenburgh JV et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
7. Peters WP, Dansey RD, Klein JL, Baynes RD. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist 2000; 5: 1-13.
8. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-1391.
9. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002; 20: 743-750.
10. Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302-1308.
11. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309-1317.
12. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 1999; 17: 3450-3456.
13. Bhatia S, Abonour R, Porcu P et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18: 3346-3351.
14. Waselenko JK, Caton J, Atkins MY et al. Salvage chemotherapy significantly prolongs survival in patients with breast cancer who relapse after high-dose chemotherapy. Blood 1999; 94: 353a (abstract).
15. Cook S, Penson R, Duska L et al. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer. Gynecol Oncol 2000; 77: 48-54.
16. Kollmannsberger C, Schleucher N, Rick O et al. Outcome of patients with 'poor prognosis' germ cell cancer relapsing after primary high-dose chemotherapy plus stem cell support (pHD-CT/PBSCT). Proc Am Soc Clin Oncol 2002; 21: 199a (abstract).
17. Bokemeyer C, Gerl A, Schöffski P et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999; 17: 512-516.
18. Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20: 2031-2037.
19. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-984.
20. Nieboer P, de Vries EG, Mulder NH et al. Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours. Bone Marrow Transplant 2001; 27: 959-966.